Darling to co-chair RTOG lung cancer committee
Gail Darling, MD, of Toronto General Hospital in Ontario, has been appointed thoracic surgery co-chair of the lung cancer committee for the Radiation Therapy Oncology Group (RTOG).
Darling is a professor of thoracic surgery and the Kress Family Chair in Esophageal Cancer at the University of Toronto. She also is director of clinical research for thoracic surgery and director of the esophageal function laboratory at Toronto General Hospital. RTOG is an international National Cancer Institute-funded clinical trials research group and is administered by the American College of Radiology.
As the surgical co-chair of the RTOG Lung Cancer Committee, Darling will work with committee chair Jeffrey D. Bradley, MD, of Washington University in St. Louis, Mo., and provide direction regarding the surgical components of RTOG lung cancer clinical trials. She also will serve as a member of the RTOG Surgical Oncology Committee chaired by Peter W.T. Pisters, MD, of MD Anderson Cancer Center in Houston.
“I have closely followed the advances made in lung cancer treatment resulting from RTOG’s clinical trials and am excited to be a part of these research efforts,” commented Darling. “In particular, the evident multidisciplinary research approach is crucial for making significant strides in lung cancer treatment.”
Darling succeeds Harvey Pass, MD, of New York University Langone Medical Center in New York City, who served as surgical co-chair of the Lung Cancer Committee since 2006.
Darling is a professor of thoracic surgery and the Kress Family Chair in Esophageal Cancer at the University of Toronto. She also is director of clinical research for thoracic surgery and director of the esophageal function laboratory at Toronto General Hospital. RTOG is an international National Cancer Institute-funded clinical trials research group and is administered by the American College of Radiology.
As the surgical co-chair of the RTOG Lung Cancer Committee, Darling will work with committee chair Jeffrey D. Bradley, MD, of Washington University in St. Louis, Mo., and provide direction regarding the surgical components of RTOG lung cancer clinical trials. She also will serve as a member of the RTOG Surgical Oncology Committee chaired by Peter W.T. Pisters, MD, of MD Anderson Cancer Center in Houston.
“I have closely followed the advances made in lung cancer treatment resulting from RTOG’s clinical trials and am excited to be a part of these research efforts,” commented Darling. “In particular, the evident multidisciplinary research approach is crucial for making significant strides in lung cancer treatment.”
Darling succeeds Harvey Pass, MD, of New York University Langone Medical Center in New York City, who served as surgical co-chair of the Lung Cancer Committee since 2006.